Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

Accurate etiologic diagnosis provides an appropriate secondary prevention and better prognosis in ischemic stroke (IS) patients; still, 45% of IS are cryptogenic, urging us to enhance diagnostic precision. We have studied the transcriptomic content of plasma extracellular vesicles (EVs) ( = 21) to identify potential biomarkers of IS etiologies. The proteins encoded by the selected genes were measured in the sera of IS patients ( = 114) and in hypertensive patients with ( = 78) and without atrial fibrillation (AF) ( = 20). IGFBP-2, the most promising candidate, was studied using immunohistochemistry in the IS thrombi ( = 23) and atrium of AF patients ( = 13). In vitro, the IGFBP-2 blockade was analyzed using thromboelastometry and endothelial cell cultures. We identified 745 differentially expressed genes among EVs of cardioembolic, atherothrombotic, and ESUS groups. From these, IGFBP-2 (cutoff > 247.6 ng/mL) emerged as a potential circulating biomarker of embolic IS [OR = 8.70 (1.84-41.13) = 0.003], which was increased in patients with AF vs. controls ( < 0.001) and was augmented in cardioembolic vs. atherothrombotic thrombi ( < 0.01). Ex vivo, the blockage of IGFBP-2 reduced clot firmness ( < 0.01) and lysis time ( < 0.001) and in vitro, diminished endothelial permeability ( < 0.05) and transmigration ( = 0.06). IGFBP-2 could be a biomarker of embolic IS and a new therapeutic target involved in clot formation and endothelial dysfunction.